Question
Does the combination of baricitinib and remdesivir improve outcomes in patients hospitalized with COVID-19?
Conclusion
For hospitalized patients with COVID-19 and evidence of lower respiratory tract infection, the combination of baracitinib plus remdesivir results in faster time to recovery, especially in patients who require noninvasive mechanical ventilation or high-flow oxygen. No survival benefit is seen with this combination.
Recent Posts
- How do ibuprofen, ketorolac, and diclofenac compare for the treatment of acute, nonradicular low back pain in adults?
- Is there an association between gastric cancer and the use of proton pump inhibitors?
- Is leukocyte-rich plasma less effective than leukocyte-poor plasma when injected into the knees of adults with osteoarthritis?
- Is an intramuscular glucocorticoid injection noninferior to an intra-articular glucocorticoid injection in reducing knee pain in adults with knee osteoarthritis?
- Are postoperative opioids more effective than nonopioids in reducing pain after minor or moderate surgical procedures?
Leave A Comment